

Registration No. 333-272895  
Registration No. 333-273887  
Registration No. 333-195211  
Registration No. 333-198289  
Registration No. 333-202941  
Registration No. 333-210453  
Registration No. 333-216905  
Registration No. 333-223687  
Registration No. 333-226741  
Registration No. 333-229953  
Registration No. 333-254697  
Registration No. 333-263644  
Registration No. 333-270795

---

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

---

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8**  
**REGISTRATION STATEMENTS**

NOS. 333-272895, 333-273887

**POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8**  
**REGISTRATION STATEMENTS**

NOS. 333-195211, 333-198289, 333-202941, 333-210453, 333-216905, 333-223687, 333-226741, 333-229953, 333-254697, 333-263644, 333-270795

*UNDER*  
*THE SECURITIES ACT OF 1933*

---

**CYMABAY THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

Delaware  
(State or other jurisdiction of  
incorporation or organization)

94-3103561  
(I.R.S. Employer  
Identification No.)

7601 Dumbarton Circle  
Fremont, CA  
(Address of Principal Executive Offices)

94555  
(Zip Code)

(510) 293-8800  
(Registrant's telephone number, including area code)

CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan  
CymaBay Therapeutics, Inc. 2023 Equity Incentive Plan  
2020 New Hire Plan  
(Full title of the plans)

Paul Quinlan  
General Counsel  
CymaBay Therapeutics, Inc.  
7601 Dumbarton Circle  
Fremont, CA 94555  
(510) 293-8800

(Name and address, including zip code, and telephone number, including area code, of agent for service)

---

*Copies to:*

Richard Hall  
Matthew L. Ploszek  
Cravath, Swaine & Moore LLP  
Worldwide Plaza  
825 Eighth Avenue  
New York, New York 10019  
(212) 474-1000

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, anon-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Non-accelerated filer

Accelerated filer

Smaller reporting company

Emerging Growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

---

---

**EXPLANATORY NOTE  
DEREGISTRATION OF SECURITIES**

CymaBay Therapeutics, Inc., a Delaware corporation (the “Registrant”), is filing these Post-Effective Amendments (these “Post-Effective Amendments”) to the following Registration Statements on Form S-8 (each, a “Registration Statement” and, collectively, the “Registration Statements”), previously filed by the Registrant with the U.S. Securities and Exchange Commission (the “SEC”), to deregister any and all shares of the Registrant’s common stock, par value \$0.0001 per share (the “Common Stock”), registered but unsold or otherwise unissued under each such Registration Statement as of the date hereof:

- Registration Statement on [Form S-8](#) (Registration File No. 333-195211), which was filed with the SEC on April 11, 2014, as amended by that certain [Post-Effective Amendment No. 1](#), which was filed with the SEC on August 10, 2023, pertaining to the registration of 1,049,716 shares of Common Stock in the aggregate under the Metabolex, Inc. 2003 Equity Incentive Plan, the CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan (the “2013 Plan”) and the CymaBay Therapeutics, Inc. 2023 Equity Incentive Plan (the “2023 Plan”);
- Registration Statement on [Form S-8](#) (Registration File No. 333-198289), which was filed with the SEC on August 21, 2014, as amended by that certain [Post-Effective Amendment No. 1](#), which was filed with the SEC on August 10, 2023, pertaining to the registration of 500,000 shares of Common Stock under the 2013 Plan and the 2023 Plan;
- Registration Statement on [Form S-8](#) (Registration File No. 333-202941), which was filed with the SEC on March 23, 2015, as amended by that certain [Post-Effective Amendment No. 1](#), which was filed with the SEC on August 10, 2023, pertaining to the registration of 734,805 shares of Common Stock under the 2013 Plan and the 2023 Plan;
- Registration Statement on [Form S-8](#) (Registration File No. 333-210453), which was filed with the SEC on March 29, 2016, as amended by that certain [Post-Effective Amendment No. 1](#), which was filed with the SEC on August 10, 2023, pertaining to the registration of 1,172,350 shares of Common Stock under the 2013 Plan and the 2023 Plan;
- Registration Statement on [Form S-8](#) (Registration File No. 333-216905), which was filed with the SEC on March 23, 2017, as amended by that certain [Post-Effective Amendment No. 1](#), which was filed with the SEC on August 10, 2023, pertaining to the registration of 1,172,350 shares of Common Stock under the 2013 Plan and the 2023 Plan;
- Registration Statement on [Form S-8](#) (Registration File No. 333-223687), which was filed with the SEC on March 15, 2018, as amended by that certain [Post-Effective Amendment No. 1](#), which was filed with the SEC on August 10, 2023, pertaining to the registration of 2,220,439 shares of Common Stock under the 2013 Plan and the 2023 Plan;
- Registration Statement on [Form S-8](#) (Registration File No. 333-226741), which was filed with the SEC on August 9, 2018, as amended by that certain [Post-Effective Amendment No. 1](#), which was filed with the SEC on August 10, 2023, pertaining to the registration of 1,500,000 shares of Common Stock under the 2013 Plan and the 2023 Plan;
- Registration Statement on [Form S-8](#) (Registration File No. 333-229953), which was filed with the SEC on February 28, 2019, as amended by that certain [Post-Effective Amendment No. 1](#), which was filed with the SEC on August 10, 2023, pertaining to the registration of 2,378,259 shares of Common Stock under the 2013 Plan and the 2023 Plan;
- Registration Statement on [Form S-8](#) (Registration File No. 333-254697), which was filed with the SEC on March 25, 2021, as amended by that certain [Post-Effective Amendment No. 1](#), which was filed with the SEC on August 10, 2023, pertaining to the registration of 3,507,843 shares of Common Stock in the aggregate under the 2013 Plan, the 2020 New Hire Plan (the “2020 Plan”) and the 2023 Plan;

- 
- Registration Statement on [Form S-8](#) (Registration File No. 333-263644), which was filed with the SEC on March 17, 2022, as amended by that certain [Post-Effective Amendment No. 1](#), which was filed with the SEC on August 10, 2023, pertaining to the registration of 4,233,896 shares of Common Stock under the 2013 Plan and the 2023 Plan;
  - Registration Statement on [Form S-8](#) (Registration File No. 333-270795), which was filed with the SEC on March 23, 2023, as amended by that certain [Post-Effective Amendment No. 1](#), which was filed with the SEC on August 10, 2023, pertaining to the registration of 4,234,053 shares of Common Stock under the 2013 Plan and the 2023 Plan;
  - Registration Statement on [Form S-8](#) (Registration File No. 333-272895), which was filed with the SEC on June 23, 2023, pertaining to the registration of 6,000,000 shares of Common Stock under the 2023 Plan; and
  - Registration Statement on [Form S-8](#) (Registration File No. 333-273887), which was filed with the SEC on August 10, 2023, pertaining to the registration of 1,000,000 shares of Common Stock under the 2020 Plan.

On February 11, 2024, the Registrant entered into that certain Agreement and Plan of Merger with Gilead Sciences, Inc., a Delaware corporation (“Parent”), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), pursuant to which, among other things, Purchaser merged with and into the Registrant (the “Merger”), with the Registrant continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent. The Merger became effective on March 22, 2024, pursuant to a certificate of merger filed with the Secretary of State of the State of Delaware.

In connection with the Merger, the Registrant has terminated any and all of the offerings of the Registrant’s securities pursuant to the Registration Statements. In accordance with the undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unsold at the termination of the offerings, the Registrant hereby amends the Registration Statements and removes from registration any and all of the securities of the Registrant registered under the Registration Statements that remain unsold as of the date hereof, and hereby terminates the effectiveness of each of the Registration Statements.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, California, on March 22, 2024.

CymaBay Therapeutics, Inc.

By: /s/ Paul Quinlan

Name: Paul Quinlan

Title: General Counsel

\* Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments to the Registration Statements.